Report Highlights

Tonsil Cancer in the United States: Market Overview

The U.S. tonsil cancer market covers diagnostics, surgery, radiotherapy, systemic drugs and supportive care for squamous cell carcinoma of the tonsil, the largest subsite within oropharyngeal cancer. The American Cancer Society projects more than 54,000 new oral cavity and pharyngeal cancers in 2024, with HPV-associated oropharyngeal disease now the dominant driver. Analyst estimates place 2024 treatment-related spend at USD 2.6 billion, concentrated in hospital outpatient infusion, radiation oncology and robotic surgery.

Government has led prevention and reimbursement, while private companies lead therapeutics and devices. ACIP recommendations for HPV vaccination, made available without cost-sharing under Section 2713 of the Public Health Service Act as added by the Patient Protection and Affordable Care Act, are reducing future incidence. The National Cancer Institute, funded at about USD 7.2 billion in FY2024, financed the trials establishing PD-1 blockade in head and neck cancer, while Merck's Keytruda and Intuitive Surgical's da Vinci platform were commercialized by industry.

Policy-Driven Growth in U.S. Tonsil Cancer Care

Medicare Part B reimbursement drives growth in intravenous immunotherapy. Under the Medicare Physician Fee Schedule's average sales price methodology, drug acquisition is paid at ASP plus 6 percent, enabling community oncology practices to administer pembrolizumab and nivolumab for recurrent or metastatic head and neck squamous cell carcinoma. This margin converts directly into treatment capacity, as practices add infusion chairs to meet rising referral volumes.

The Inflation Reduction Act of 2022 adds a USD 2,000 Part D out-of-pocket cap from 2025, which lifts adherence to oral antiemetics and supportive agents used during chemoradiotherapy. The Food and Drug Omnibus Reform Act of 2022 formalized confirmatory-trial requirements for accelerated approvals, shaping how sponsors sequence label expansions. National Cancer Institute cooperative group trials, including NRG Oncology's RTOG 1016, sustain demand by establishing cisplatin-based chemoradiotherapy as the standard for HPV-positive oropharyngeal cancer.

Regulatory Barriers and Compliance Costs

Certificate of Need programmes, administered by state health departments in roughly 35 states, gate radiotherapy capacity. Establishing a new radiation oncology service, including linear accelerators and brachytherapy suites, typically requires CON approval that adds six to twelve months and application costs running into six figures. Medicare prior authorization requirements, codified under the CMS Interoperability and Prior Authorization Final Rule, add further administrative delay before immunotherapy can begin.

FDA's Center for Devices and Radiological Health regulates transoral robotic surgery and radiotherapy hardware under the Federal Food, Drug, and Cosmetic Act. New robotic instruments require 510(k) clearance with an MDUFA performance goal of 90 FDA review days, while novel platforms need premarket approval with a 180-day goal and clinical data programmes often exceeding USD 10 million. Covered entities must also comply with Section 340B of the Public Health Service Act, administered by HRSA, which restricts duplicate discounts on oncology drugs.

Policy-Created Opportunities in U.S. Tonsil Cancer

Biosimilar development presents the clearest near-term opportunity. Under the Inflation Reduction Act, qualifying Part B biosimilars receive ASP plus 8 percent for five years, creating a commercial incentive for developers ahead of pembrolizumab's expected 2028 US exclusivity expiry. Sponsors filing under the Biologics Price Competition and Innovation Act of 2009 can target community oncology practices, where Part B margin pressure is most acute.

De-escalation trials funded by the National Cancer Institute, led by NRG Oncology's RTOG 1016, support reduced-intensity regimens for HPV-positive tonsil cancer. Lower-toxicity protocols expand eligible patient pools and favour vendors offering adaptive radiotherapy software compatible with installed Varian and Accuray linear accelerators. ACIP's 2019 shared clinical decision-making recommendation extends HPV vaccination to adults aged 27 to 45, opening a catch-up market for vaccine manufacturers.

Market at a Glance

Leading Market Participants

• Merck & Co.
• Bristol Myers Squibb
• Eli Lilly and Company
• AstraZeneca
• Intuitive Surgical
• Varian Medical Systems
• Accuray
• Karl Storz
• Olympus Corporation of the Americas
• Medtronic

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by FDA's Oncology Center of Excellence for drugs and by CDRH for devices. Reimbursement rests on Title XVIII of the Social Security Act, implemented by CMS, and on the Inflation Reduction Act of 2022, which introduced Part D out-of-pocket caps and extends Medicare drug price negotiation to Part B drugs with prices effective from 2028. Key compliance requirements include confirmatory-trial obligations for accelerated approvals, 340B duplicate discount rules, and CMS-0057-F decision deadlines beginning January 2026.

Upcoming changes include Medicare negotiation for selected Part B drugs, scheduled to take effect in 2028, and biosimilar entry after pembrolizumab exclusivity lapses. Compared with regional peers, the U.S. framework remains market-driven, whereas Canada's Patented Medicine Prices Review Board and the pan-Canadian Pharmaceutical Alliance negotiate national prices. The EU HTA Regulation, applicable to oncology medicines from January 2025, introduces joint clinical assessments across member states.

Long-Term Policy Outlook for Tonsil Cancer in the United States

By 2032, Medicare negotiation under the Inflation Reduction Act will reshape Part B immunotherapy economics, with negotiated prices and biosimilar uptake shifting value from brand manufacturers toward biosimilar developers and payers. Net pricing pressure will hold revenue growth below volume growth, moving the USD 2.6 billion base toward USD 3.9 billion in a more price-competitive market.

HPV vaccination, targeting 80 percent adolescent coverage under Healthy People 2030, will gradually reduce incidence of HPV-driven tonsil cancer across the longer horizon. Policy will increasingly favour de-escalated regimens and reimbursement for survivorship and toxicity management, reshaping the product mix across the forecast period.